Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy

Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy

Two novel series of RGD-MEKI conjugates derived from a MEK1/2 kinase inhibitor—PD0325901—have been developed for integrin receptor mediated anticancer therapy. The first series, alkoxylamine analog RGD-MEKI conjugates 9a–g showed anti-proliferation activity in melanoma A375 cells by the same mechani...

Full description

Bibliographic Details
Main Authors: Yun Wu, Zili Chen, Zhenjun Yang, Ping Xu, Hongyan He, Xinjie Liu, Chao Wang, Xiaoxiao Li, Jianjun Hou, Lihe Zhang
Format: Article
Language:English
Published: MDPI AG 2013-11-01
Series:Molecules
Subjects:
RGD-MEKI conjugate
MEK1/2 kinase inhibitor
PD0325901
RGD peptide
integrin αvβ3 receptor
tumor-targeted drug delivery
Online Access:http://www.mdpi.com/1420-3049/18/11/13957

Internet

http://www.mdpi.com/1420-3049/18/11/13957

Similar Items